Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Campone

Showing results (141-150 of 302) with videos related to

Pageof 31
Sort By:
Evolution, Medicine, and Public Health|September 22, 2025
Leveraging selection for function in tumor evolution: System-level cancer therapiesFrédéric Thomas, Jean-Pascal Capp, Antoine M Dujon, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 15, 2018
Prolonged perioperative thoracic epidural analgesia may improve survival after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A comparative studyGérard Lorimier, Valérie Seegers, Marie Coudert, et al.
Breast Cancer Research and Treatment|January 4, 2021
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trialsMatthew P Goetz, Meena Okera, Hans Wildiers, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2025
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trialsLowell L Hart, Seock-Ah Im, Sara M Tolaney, et al.
The Oncologist|June 10, 2026
Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancerJose Sandoval, Patrick Neven, Anna Emde, et al.
Cancer Immunology, Immunotherapy : CII|February 9, 2020
The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patientsPierre Rosenbaum, Cécile Artaud, Sylvie Bay, et al.
The Oncologist|October 10, 2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathyMario Campone, Dominique Berton-Rigaud, Florence Joly-Lobbedez, et al.
Plos One|May 31, 2024
Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter studyKe Zhou, Marie Robert, Valérie Seegers, et al.
Cancer Chemotherapy and Pharmacology|June 20, 2020
Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumorsMats Någård, Mei-Lin Ah-See, Karen So, et al.
Plos One|July 13, 2011
Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapyAhmed Hamaï, Karine Duperrier-Amouriaux, Pascale Pignon, et al.
Pageof 31

Showing results (141-150 of 302) with videos related to

Sort By:
Pageof 31
Evolution, Medicine, and Public Health|September 22, 2025
Leveraging selection for function in tumor evolution: System-level cancer therapiesFrédéric Thomas, Jean-Pascal Capp, Antoine M Dujon, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 15, 2018
Prolonged perioperative thoracic epidural analgesia may improve survival after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A comparative studyGérard Lorimier, Valérie Seegers, Marie Coudert, et al.
Breast Cancer Research and Treatment|January 4, 2021
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trialsMatthew P Goetz, Meena Okera, Hans Wildiers, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2025
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trialsLowell L Hart, Seock-Ah Im, Sara M Tolaney, et al.
The Oncologist|June 10, 2026
Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancerJose Sandoval, Patrick Neven, Anna Emde, et al.
Cancer Immunology, Immunotherapy : CII|February 9, 2020
The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patientsPierre Rosenbaum, Cécile Artaud, Sylvie Bay, et al.
The Oncologist|October 10, 2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathyMario Campone, Dominique Berton-Rigaud, Florence Joly-Lobbedez, et al.
Plos One|May 31, 2024
Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter studyKe Zhou, Marie Robert, Valérie Seegers, et al.
Cancer Chemotherapy and Pharmacology|June 20, 2020
Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumorsMats Någård, Mei-Lin Ah-See, Karen So, et al.
Plos One|July 13, 2011
Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapyAhmed Hamaï, Karine Duperrier-Amouriaux, Pascale Pignon, et al.
Pageof 31